Pmv Pharmaceuticals
Yahoo Finance • last month
Top Penny Stocks To Watch In November 2025
As the U.S. market experiences a downturn with major indexes like the Dow Jones dropping significantly, investors are seeking opportunities that can weather current uncertainties. Penny stocks, though an older term, remain relevant for tho... Full story
Yahoo Finance • last month
PMV Pharmaceuticals GAAP EPS of -$0.40
* PMV Pharmaceuticals press release [https://seekingalpha.com/pr/20303656-pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights] (PMVP [https://seekingalpha.com/symbol/PMVP]): Q3 GAAP EPS of -$0.40.... Full story
Yahoo Finance • 2 months ago
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head a... Full story
Yahoo Finance • 2 months ago
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C mutation PRINCETON, N... Full story
Yahoo Finance • 3 months ago
Noteworthy Monday Option Activity: SANM, HROW, ASPN
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sanmina Corp (Symbol: SANM), where a total volume of 3,360 contracts has been traded thus far today, a contract volume wh... Full story
Yahoo Finance • 4 months ago
Get insights into the top gainers and losers of Wednesday's pre-market session.
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT JBDI [https://www.chartmi... Full story
Yahoo Finance • 4 months ago
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck,colorectal, gallbladder, and ampullary carcinoma33% overall response... Full story
Yahoo Finance • 5 months ago
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-u... Full story
Yahoo Finance • 6 months ago
Ticktin Robert, general counsel, sells PMV Pharma shares for $24,651
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) General Counsel & COO, Robert Ticktin, sold 23,151 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of... Full story
Yahoo Finance • 6 months ago
Pmv Pharma CFO Carulli sells $30k in common stock
Michael Carulli, Chief Financial Officer of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), sold 28,249 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a pr... Full story
Yahoo Finance • 10 months ago
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsConfirmed responses observed in multiple tumor types including ovarian, brea... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced... Full story
Yahoo Finance • 2 years ago
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutationCompany to host KOL... Full story
Yahoo Finance • 3 years ago
PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights
Continued progress in the ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; next update is expected in 2H 2023Commence... Full story
Yahoo Finance • 3 years ago
PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in... Full story
Yahoo Finance • 3 years ago
15 Most Shorted Stocks Right Now
In this article, we discuss the 15 most shorted stocks right now. If you want to read about some more shorted stocks, go directly to 5 Most Shorted Stocks Right Now. The stock market has been volatile in the past few months as soaring inf... Full story
Yahoo Finance • 3 years ago
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation Phase 1b combination trial with Merck evaluating... Full story
Yahoo Finance • 3 years ago
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced... Full story
